Cortney A. Turner
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Cortney A. Turner has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
Huda Akil
Michigan Neuroscience Institute, University of Michigan
16 shared publicationsStanley J. Watson
Michigan Neuroscience Institute, University of Michigan, Ann Arbor, MI 48109
15 shared publicationsAlan F. Schatzberg
Department of Psychiatry & Behavioral Sciences, Stanford University, Palo Alto, California
3 shared publications- Megan Hastings Hagenauer
University of Michigan, Ann Arbor, MI 48109 USA
3 shared publications Robert C. Thompson
Molecular & Behavioral Neuroscience Institute, University of Michigan, Ann Arbor, Michigan; Department of Psychiatry, University of Michigan, Ann Arbor, Michigan
3 shared publicationsSarah M. Clinton
Molecular and Behavioral Neuroscience Institute and
3 shared publications
Latest Publications
- Open Access
- 27 November 2023
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 120 (49)
The impact of COVID-19 on a college freshman sample reveals genetic and nongenetic forms of susceptibility and resilience to stress
Using a longitudinal approach, we sought to define the interplay between genetic and nongenetic factors in shaping vulnerability or resilience to COVID-19 pandemic stress, as indexed by the emergence of symptoms of depression and/or anxiety. University of Michigan freshmen were characterized at baseline using multiple psychological instruments. Subjects were genotyped, and a polygenic risk score for depression (MDD-PRS) was calculated. Daily physical activity and sleep were captured. Subjects were sampled at multiple time points throughout the freshman year on clinical rating scales, including GAD-7 and PHQ-9 for anxiety and depression, respectively. Two cohorts (2019 to 2021) were compared to a pre-COVID-19 cohort to assess the impact of the pandemic. Across cohorts, 26 to 40% of freshmen developed symptoms of anxiety or depression (N = 331). Depression symptoms significantly increased in the pandemic years and became more chronic, especially in females. Physical activity was reduced, and sleep was increased by the pandemic, and this correlated with the emergence of mood symptoms. While low MDD-PRS predicted lower risk for depression during a typical freshman year, this genetic advantage vanished during the pandemic. Indeed, females with lower genetic risk accounted for the majority of the pandemic-induced rise in depression. We developed a model that explained approximately half of the variance in follow-up depression scores based on psychological trait and state characteristics at baseline and contributed to resilience in genetically vulnerable subjects. We discuss the concept of multiple types of resilience, and the interplay between genetic, sex, and psychological factors in shaping the affective response to different types of stressors.
- 27 November 2023
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 120 (49)
Open AccessThe impact of COVID-19 on a college freshman sample reveals genetic and nongenetic forms of susceptibility and resilience to stress
Using a longitudinal approach, we sought to define the interplay between genetic and nongenetic factors in shaping vulnerability or resilience to COVID-19 pandemic stress, as indexed by the emergence of symptoms of depression and/or anxiety. University of Michigan freshmen were characterized at baseline using multiple psychological instruments. Subjects were genotyped, and a polygenic risk score for depression (MDD-PRS) was calculated. Daily physical activity and sleep were captured. Subjects were sampled at multiple time points throughout the freshman year on clinical rating scales, including GAD-7 and PHQ-9 for anxiety and depression, respectively. Two cohorts (2019 to 2021) were compared to a pre-COVID-19 cohort to assess the impact of the pandemic. Across cohorts, 26 to 40% of freshmen developed symptoms of anxiety or depression (N = 331). Depression symptoms significantly increased in the pandemic years and became more chronic, especially in females. Physical activity was reduced, and sleep was increased by the pandemic, and this correlated with the emergence of mood symptoms. While low MDD-PRS predicted lower risk for depression during a typical freshman year, this genetic advantage vanished during the pandemic. Indeed, females with lower genetic risk accounted for the majority of the pandemic-induced rise in depression. We developed a model that explained approximately half of the variance in follow-up depression scores based on psychological trait and state characteristics at baseline and contributed to resilience in genetically vulnerable subjects. We discuss the concept of multiple types of resilience, and the interplay between genetic, sex, and psychological factors in shaping the affective response to different types of stressors.
- Open Access
Stress, Genetics and Mood: Impact of COVID-19 on a College Freshman Sample
Objectives Use a longitudinal approach to study the impact of the Covid-19 pandemic on the emergence of symptoms of depression and/or anxiety in college freshmen. Define the interplay between genetic risk and psychosocial factors in shaping vulnerability or resilience to pandemic stress. Methods University of Michigan freshmen were characterized at baseline using multiple psychological instruments. They were genotyped and polygenic risk score for depression (MDD-PRS) was calculated. Daily physical activity was captured. They were sampled at multiple time points throughout the freshman year on clinical rating scales, including GAD-7 and PHQ-9 for anxiety and depression, respectively. The 2019-2020 cohort (N=122) was compared to an earlier cohort (N=106) to assess the impact of the pandemic. Results Across cohorts, 25%-57% of freshmen developed significant symptoms of anxiety or depression. In the 2019-2020 cohort, measures of anxiety and depression increased significantly after the onset of COVID-19. Physical activity was dramatically reduced by the pandemic and was associated with the emergence of mood symptoms. Low MDD-PRS subjects exhibited lower relative risk for depression/anxiety during a typical freshman year, but they were more negatively impacted by the pandemic than High MDD-PRS subjects. Conversely, a cluster of psychological indices at baseline predicted resilience in High MDD-PRS subjects who did not develop a mood disorder post-stress. Conclusions The pandemic had a profound impact on college freshmen triggering depression and anxiety symptoms. Pandemic stress overrode the advantage conferred by “genetic resilience”. By contrast, “psychosocial resilience” was protective even in the face of high genetic risk and pandemic stress.
Open AccessStress, Genetics and Mood: Impact of COVID-19 on a College Freshman Sample
Objectives Use a longitudinal approach to study the impact of the Covid-19 pandemic on the emergence of symptoms of depression and/or anxiety in college freshmen. Define the interplay between genetic risk and psychosocial factors in shaping vulnerability or resilience to pandemic stress. Methods University of Michigan freshmen were characterized at baseline using multiple psychological instruments. They were genotyped and polygenic risk score for depression (MDD-PRS) was calculated. Daily physical activity was captured. They were sampled at multiple time points throughout the freshman year on clinical rating scales, including GAD-7 and PHQ-9 for anxiety and depression, respectively. The 2019-2020 cohort (N=122) was compared to an earlier cohort (N=106) to assess the impact of the pandemic. Results Across cohorts, 25%-57% of freshmen developed significant symptoms of anxiety or depression. In the 2019-2020 cohort, measures of anxiety and depression increased significantly after the onset of COVID-19. Physical activity was dramatically reduced by the pandemic and was associated with the emergence of mood symptoms. Low MDD-PRS subjects exhibited lower relative risk for depression/anxiety during a typical freshman year, but they were more negatively impacted by the pandemic than High MDD-PRS subjects. Conversely, a cluster of psychological indices at baseline predicted resilience in High MDD-PRS subjects who did not develop a mood disorder post-stress. Conclusions The pandemic had a profound impact on college freshmen triggering depression and anxiety symptoms. Pandemic stress overrode the advantage conferred by “genetic resilience”. By contrast, “psychosocial resilience” was protective even in the face of high genetic risk and pandemic stress.
- 1 October 2018
- Published by Elsevier in Biological Psychiatry
- Vol. 84 (8) , 555-562
Connective Tissue Growth Factor Is a Novel Prodepressant
- 1 October 2018
- Published by Elsevier in Biological Psychiatry
- Vol. 84 (8) , 555-562
Connective Tissue Growth Factor Is a Novel Prodepressant
- 9 April 2018
- Published by Springer Nature in Neuropsychopharmacology
- Vol. 44 (2) , 356-363
Neural cell adhesion molecule peptide mimetics modulate emotionality: pharmacokinetic and behavioral studies in rats and non-human primates
Recent evidence highlights the fibroblast growth factor (FGF) family in emotion modulation. Although ligands that activate FGF receptors have antidepressant and anxiolytic effects in animal models, FGF ligands have a broad range of actions both in the brain and the periphery. Therefore, identifying molecular partners that may function as allosteric modulators could offer new avenues for drug development. Since neural cell adhesion molecule (NCAM) activates FGF receptors, we asked whether peripherally administered NCAM peptide mimetics penetrate the brain and alter the behavior of standardized tests that have predictive validity for drug treatments of anxiety or depression. The NCAM peptide mimetic, plannexin, acutely increased and chronically decreased anxiety, but did not have antidepressant effects in rats. Another NCAM peptide mimetic, FGLL, had acute anxiogenic effects and chronic antidepressant effects in rats. A related NCAM peptide mimetic, FGLS, had antidepressant effects without modulating anxiety-like behavior, and these antidepressant effects were blocked by an AMPA receptor antagonist. Cisternal cerebrospinal fluid (CSF) levels of FGLs correlated with blood plasma levels in rats and non-human primates, and CSF-to-blood ratios of FGLS were comparable in both species. Results indicate that NCAM peptide mimetics penetrate the brain and support the suggestion that FGLS may be a candidate for further development as a novel treatment for major depressive disorder in humans.
- 9 April 2018
- Published by Springer Nature in Neuropsychopharmacology
- Vol. 44 (2) , 356-363
Neural cell adhesion molecule peptide mimetics modulate emotionality: pharmacokinetic and behavioral studies in rats and non-human primates
Recent evidence highlights the fibroblast growth factor (FGF) family in emotion modulation. Although ligands that activate FGF receptors have antidepressant and anxiolytic effects in animal models, FGF ligands have a broad range of actions both in the brain and the periphery. Therefore, identifying molecular partners that may function as allosteric modulators could offer new avenues for drug development. Since neural cell adhesion molecule (NCAM) activates FGF receptors, we asked whether peripherally administered NCAM peptide mimetics penetrate the brain and alter the behavior of standardized tests that have predictive validity for drug treatments of anxiety or depression. The NCAM peptide mimetic, plannexin, acutely increased and chronically decreased anxiety, but did not have antidepressant effects in rats. Another NCAM peptide mimetic, FGLL, had acute anxiogenic effects and chronic antidepressant effects in rats. A related NCAM peptide mimetic, FGLS, had antidepressant effects without modulating anxiety-like behavior, and these antidepressant effects were blocked by an AMPA receptor antagonist. Cisternal cerebrospinal fluid (CSF) levels of FGLs correlated with blood plasma levels in rats and non-human primates, and CSF-to-blood ratios of FGLS were comparable in both species. Results indicate that NCAM peptide mimetics penetrate the brain and support the suggestion that FGLS may be a candidate for further development as a novel treatment for major depressive disorder in humans.
- 1 April 2017
- Published by Elsevier in Current Opinion in Behavioral Sciences
- Vol. 14, 108-114
Utilizing a unique animal model to better understand human temperament
- 1 April 2017
- Published by Elsevier in Current Opinion in Behavioral Sciences
- Vol. 14, 108-114
Utilizing a unique animal model to better understand human temperament
- 1 September 2016
- Published by Elsevier in Biological Psychiatry
- Vol. 80 (6) , 419-421
Fibroblast Growth Factor 2 Sits at the Interface of Stress and Anxiety
- 1 September 2016
- Published by Elsevier in Biological Psychiatry
- Vol. 80 (6) , 419-421
Fibroblast Growth Factor 2 Sits at the Interface of Stress and Anxiety
- 1 May 2016
- Published by Elsevier in Seminars in Cell & Developmental Biology
- Vol. 53, 136-143
Dysregulated fibroblast growth factor (FGF) signaling in neurological and psychiatric disorders
- 1 May 2016
- Published by Elsevier in Seminars in Cell & Developmental Biology
- Vol. 53, 136-143
Dysregulated fibroblast growth factor (FGF) signaling in neurological and psychiatric disorders
- Open Access
- 22 April 2014
- Published by Frontiers Media SA in Frontiers in Human Neuroscience
- Vol. 8, 238
Altered choroid plexus gene expression in major depressive disorder
Given the emergent interest in biomarkers for mood disorders, we assessed gene expression in the choroid plexus (CP), the region that produces cerebrospinal fluid (CSF), in individuals with major depressive disorder (MDD). Genes that are expressed in the CP can be secreted into the CSF and may be potential biomarker candidates. Given that we have previously shown that fibroblast growth factor family members are differentially expressed in post-mortem brain of subjects with MDD and the CP is a known source of growth factors in the brain, we posed the question whether growth factor dysregulation would be found in the CP of subjects with MDD. We performed laser capture microscopy of the CP at the level of the hippocampus in subjects with MDD and psychiatrically normal controls. We then extracted, amplified, labeled, and hybridized the cRNA to Illumina BeadChips to assess gene expression. In controls, the most highly abundant known transcript was transthyretin. Moreover, half of the 14 most highly expressed transcripts in controls encode ribosomal proteins. Using BeadStudio software, we identified 169 transcripts differentially expressed (p < 0.05) between control and MDD samples. Using pathway analysis we noted that the top network altered in subjects with MDD included multiple members of the transforming growth factor-beta (TGFβ) pathway. Quantitative real-time PCR (qRT-PCR) confirmed downregulation of several transcripts that interact with the extracellular matrix in subjects with MDD. These results suggest that there may be an altered cytoskeleton in the CP in MDD subjects that may lead to a disrupted blood-CSF-brain barrier.
- 22 April 2014
- Published by Frontiers Media SA in Frontiers in Human Neuroscience
- Vol. 8, 238
Open AccessAltered choroid plexus gene expression in major depressive disorder
Given the emergent interest in biomarkers for mood disorders, we assessed gene expression in the choroid plexus (CP), the region that produces cerebrospinal fluid (CSF), in individuals with major depressive disorder (MDD). Genes that are expressed in the CP can be secreted into the CSF and may be potential biomarker candidates. Given that we have previously shown that fibroblast growth factor family members are differentially expressed in post-mortem brain of subjects with MDD and the CP is a known source of growth factors in the brain, we posed the question whether growth factor dysregulation would be found in the CP of subjects with MDD. We performed laser capture microscopy of the CP at the level of the hippocampus in subjects with MDD and psychiatrically normal controls. We then extracted, amplified, labeled, and hybridized the cRNA to Illumina BeadChips to assess gene expression. In controls, the most highly abundant known transcript was transthyretin. Moreover, half of the 14 most highly expressed transcripts in controls encode ribosomal proteins. Using BeadStudio software, we identified 169 transcripts differentially expressed (p < 0.05) between control and MDD samples. Using pathway analysis we noted that the top network altered in subjects with MDD included multiple members of the transforming growth factor-beta (TGFβ) pathway. Quantitative real-time PCR (qRT-PCR) confirmed downregulation of several transcripts that interact with the extracellular matrix in subjects with MDD. These results suggest that there may be an altered cytoskeleton in the CP in MDD subjects that may lead to a disrupted blood-CSF-brain barrier.